{
    "nctId": "NCT03546478",
    "briefTitle": "99mTc Labelled Affibody SPECT/CT Imaging for Breast Cancer HER2 Characterization",
    "officialTitle": "99mTc Labelled Affibody SPECT/CT Imaging for Breast Cancer HER2 Characterization",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 32,
    "primaryOutcomeMeasure": "T/B",
    "eligibilityCriteria": "Inclusion Criteria:\n\nPatients with breast cancer before surgery Conventional imaging within 1 month Signed written consent Age above 29 years Female\n\nExclusion Criteria:\n\nPregnancy Breastfeeding Renal function: serum creatinine \\> 3.0 mg/dl Known allergy against affibody Any medical condition that, in the opinion of the investigator, may significantly interfere with study compliance",
    "sex": "FEMALE",
    "minimumAge": "29 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}